Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC adaptor. The company was founded in 2016 and is headquartered in Daejeon, South Korea.
Metrics to compare | 475830 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship475830PeersSector | |
|---|---|---|---|---|
P/E Ratio | −72.7x | −22.9x | −0.5x | |
PEG Ratio | 0.27 | −0.80 | 0.00 | |
Price/Book | 18.5x | 4.0x | 2.6x | |
Price / LTM Sales | 105,237.4x | 12.9x | 3.1x | |
Upside (Analyst Target) | - | 58.7% | 57.5% | |
Fair Value Upside | Unlock | 9.5% | 8.1% | Unlock |